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Abstract
Accumulating evidence suggests that glucolipotoxicity, arising from the combined actions of elevated glucose and free
fatty acid levels, acts as a key pathogenic component in type II diabetes, contributing to b-cell dysfunction and death.
Endoplasmic reticulum (ER) stress is among the molecular pathways and regulators involved in these negative effects, and
ceramide accumulation due to glucolipotoxicity can be associated with the induction of ER stress. Increased levels of
ceramide in ER may be due to enhanced ceramide biosynthesis and/or decreased ceramide utilization. Here, we studied the
effect of glucolipotoxic conditions on ceramide traffic in INS-1 cells in order to gain insights into the molecular
mechanism(s) of glucolipotoxicity. We showed that glucolipotoxicity inhibited ceramide utilization for complex sphingolipid
biosynthesis, thereby reducing the flow of ceramide from the ER to Golgi. Glucolipotoxicity impaired both vesicular- and
CERT-mediated ceramide transport through (1) the decreasing of phospho-Akt levels which in turn possibly inhibits
vesicular traffic, and (2) the reducing of the amount of active CERT mainly due to a lower protein levels and increased
protein phosphorylation to prevent its localization to the Golgi. In conclusion, our findings provide evidence that
glucolipotoxicity-induced ceramide overload in the ER, arising from a defect in ceramide trafficking may be a mechanism
that contributes to dysfunction and/or death of b-cells exposed to glucolipotoxicity.
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Introduction
Glucolipotoxicity is defined as the condition in which the
combined action of elevated glucose and free fatty acid (FFA) levels
synergizes in exerting deleterious effects on pancreatic b-cell
function and survival [1–3]. Accumulating evidence suggests that
this condition acts as a key pathogenic component in type II
diabetes, contributing to b-cell dysfunction and death during the
development of this disease (reviewed in [4]). In agreement,
chronic exposure of b-cells to supraphysiological levels of glucose
and free fatty acids (FFAs) has been shown to be cytotoxic and
cause b-cell dysfunction and failure [5]. Palmitate, a major FFA
species in which b-cells might be exposed to in vivo [6], is
particularly potent in reducing b-cell viability of clonal and
primary rodent b-cells, as well as in human islets [7–9].
Hyperglycaemia has been shown to potentiate the negative effects
of high levels of saturated FFAs on pancreatic b-cells [1,2]. While
palmitate and other saturated FFAs exhibit low toxicity at low
glucose concentrations, they have been shown to synergize with
elevated glucose concentrations to promote b-cell apoptosis, both
in the b-cell line INS-1 and in human islets [10–12].
Several mechanisms have been proposed for glucolipotoxicity-
induced b-cell dysfunction and failure, and, among them,
endoplasmic reticulum (ER) stress and elevations of the proapop-
totic sphingolipid ceramide (Cer) appear to play key roles.
Additionally, these two processes appear to be strictly connected
[13–15].
Several enzymes of Cer metabolism have been shown to be
involved in regulating its levels in b-cells in response to lipotoxicity
and/or glucolipotoxicity. In particular, serine palmitoyltransferase
(SPT) and ceramide synthase (CerS), both residing in the
endoplasmic reticulum (ER), and involved in Cer biosynthesis
[12,16,17], as well as neutral sphingomyelinase (N-SMase), involved
in Cer degradation [18,19], have emerged as important regulators
of elevated Cer levels. In addition, the over-expression of glucosyl-
ceramide synthase, which converts Cer into glucosyl-ceramide
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(GlcCer), has been shown to prevent b-cell apoptosis [20].
Altogether these data suggest that the accumulation of Cer in the
ER compartment of b-cells is crucial in determining b-cell fate, i.e.,
survival or death.
While the accumulation of Cer at the ER consequent to
glucolipotoxicity appears to be critically involved in the induction
of ER stress (reviewed in [15]), the dysregulation of Cer
metabolism alone may not necessarily lead to Cer accumulation
in the ER unless Cer traffic from the ER to the Golgi is inhibited.
Cer synthesized in the ER is transferred to the Golgi where it is
subsequently converted to sphingomyelin (SM), GlcCer and more
complex glycosphingolipids (GSLs) [21]. Evidence to date
indicates that there are two pathways by which Cer is transported
from the ER to the Golgi: a protein-mediated transport, by the
soluble ceramide transfer protein CERT (for SM formation) [22–
25], and a CERT-independent vesicular traffic (for the biosyn-
thesis of SM or GlcCer) [23,25,26]. The two modes of Cer
transport coexist separately contributing to the regulation of Cer
metabolism and levels in cells. For example, hyperphosphorylation
of a serine repeat motif of CERT impairs its binding to the ER and
Golgi membranes, thereby inhibiting Cer transfer from the ER to
the Golgi [22,27,28]. Additionally, nitric oxide or the overexpres-
sion of sphingosine-1-phosphate phosphohydrolase 1 (SPP1)
inhibits Cer vesicular traffic [26,29], resulting in Cer accumulation
in the ER. Notwithstanding, our knowledge on the effect of
glucolipotoxicity on Cer transport is scarce.
The aim of this investigation was to determine if the transport
mechanisms of Cer from the ER to the Golgi are involved in the
deleterious effects of glucolipotoxicity in b-cells, and to gain a
further understanding of the relationship between Cer accumula-
tion and ER stress. We demonstrate, using INS-1 cells as a model,
which can be expanded to quantities sufficient for diverse
experimentation, that palmitate and elevated glucose administra-
tion induced a rapid and potent inhibitory effect on the
mechanisms of Cer transport, resulting in the accumulation of
Cer at the ER.
Material and Methods
Materials
All reagents were of analytical grade unless otherwise stated.
The tissue culture medium RPMI 1640 was purchased from
Lonza (Basel, Switzerland). L-glutamine, sodium pyruvate solu-
tion, penicillin/streptomycin, dimethyl sulfoxide (DMSO), palmi-
tate, glucose, Hepes, bovine serum albumin fraction V (BSA), fatty
acid free-BSA, 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl tetrazoli-
um bromide (MTT), leupeptin, aprotinin, wortmannin (Wm),
Thapsigargin (Tg), Kodak Biomax film, HPLC grade water,
tetrahydrofuran (THF), methanol, LC-MS grade water, formic
acid and ammonium formate were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Fetal calf serum (FCS) was from Euroclone
(Pero, Milano, Italy). LY294002 was from Cayman Chemical
(Ann Arbor, MI, USA). Lipofectamine 2000 and the Stealth RNAi
were from Invitrogen (Carlsbad, CA, USA). D-erythro-
[3-3H]sphingosine (Sph) (19.7 Ci/mmol), was from PerkinElmer
Life Science (Boston, MA, USA). Pepstatin was from Roche
Applied Sciences (Mannheim, Germany). High performance thin
layer chromatography (HPTLC) silica gel plates were from Merck
(Darmstadt, Germany). The Golgi marker Texas red wheat germ
agglutinin (WGA), 6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ami-
no) hexanoyl) sphingosine (NBD-C6Cer) and N-(4,4,-difluoro-5-,7-
dimethyl-bora-3a,4a-diaza-sindacene- 3-pentanoyl) sphingosine
(BODIPY-C5Cer) were from Life Technologies (Italy). The
antibodies recognizing Phospho-Akt (Ser473) were from Cell
Signaling Technology, Inc. (Danvers, MA, USA); polyclonal
antibodies against Cer transfer protein (CERT) from Bethyl
Laboratories (Montgomery, TX, USA). Primary mouse monoclo-
nal anti-phospho-serine, goat anti-GRP78 and rabbit anti-
GAPDH antibodies, and secondary HRP-conjugated anti-rabbit
or anti-goat antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Secondary anti-mouse HRP-conjugated
antibody, SuperSignal WestPico Chemioluminescent Substrate
and SuperSignal WestFemto Maximum Sensitivity Substrate were
from Thermo Scientific (Rockford, IL, USA). Ceramide/Sphin-
goid Internal Standard Mixture I from Avanti Polar Lipids
(Alabaster, Alabama, USA) was used for quantitative analysis. The
plasmid of CERT tagged with green fluorescent protein (CERT-
GFP) was kindly provided by Dr. Maria Antonietta De Matteis,
Telethon Institute of Genetics and Medicine, Napoli (Italy).
Cell culture conditions
Rat insulinoma INS-1 cells, kindly provided by Merck–Serono,
were grown in RPMI 1640 medium buffered with 10 mM Hepes
containing 10% (v/v) FCS, 2 mM L-glutamine, 1 mM sodium
pyruvate, 50 mM 2-mercaptoethanol and 100 units/ml penicillin/
streptomycin at 37uC in an atmosphere of 5% CO2 and 95%
humidified air. Before each experiment, INS-1cells plated at
26105 cell/cm2 were cultured for 24 h in RPMI 1640 plus 10%
FCS. Cells were then cultured in the presence of 5 mM or 30 mM
glucose with or without 0.4 mM palmitate for 12 h; incubation in
the presence of 30 mM glucose and 0.4 mM palmitate mimics
glucolipotoxicity conditions. When indicated, the cells were
preincubated with 20 mM LY294002, or 10 nM Wm or 0.1 mM
Tg for 30 min. Palmitate was administered to the cells as a
conjugate with fatty-acid-free BSA. Briefly, dried aliquots of
palmitate in ethanol were dissolved in PBS containing 5% (w/v)
BSA to obtain a 4 mM stock solution. The molar ratio of FFAs to
BSA was 5:1. The FFA stock solutions were diluted in RPMI 1640
medium supplemented with 1% FCS to obtain a 0.4 mM final
concentration at a fixed concentration of 0.5% BSA.
Analysis of cell viability
Cell viability was determined by MTT assay. INS-1 cells were
plated and grown on a glass coverslip and cultured in the presence
of 5 mM or 30 mM glucose with or without 0.4 mM palmitate for
12 h, as previously described, or for 24 hours. At the end of the
treatments, the medium was replaced by MTT dissolved in fresh
medium (0.8 mg/ml) for 4 hours. The formazan crystals were
then solubilized in isopropanol/formic acid (95:5 v/v) for
10 minutes and the absorbance (570 nm) was measured using a
microplate reader (Wallack Multilabel Counter, Perkin Elmer,
Boston, MA, USA).
RNA interference
Small interfering RNA (siRNA) duplexes for rat CERT (Gene
accession number XM 345143.1) S87, S522 and control non-
targeting siRNAs (scrambled sequences of S87 and S522
oligonucleotides) described in [23] were used. We used Stealth
RNAi, the chemically modified synthetic RNAi duplexes that
virtually eliminate the induction of non-specific cellular stress
response, and that also improve the specific, effective knock-down
of gene expression. INS-1 cells plated at 26105 cell/cm2 were
maintained for 24 h in RPMI 1640 plus 10% FCS and then
transfected in the same medium with a 1:1 (by mol) mix of S87 +
S522 (si-CERT) or the non-targeting corresponding sequences (si-
CT) using LipofectAMINE 2000 according to the manufacturer’s
protocol. The final concentration of siRNA–lipofectamine duplex
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mixture was 100 nM. All the experiments were performed 72 h
after transfection.
Plasmid Transfection
INS-1 cells were plated at 26105 cell/cm2 on a glass coverslip
and grown in RPMI 1640 supplemented with 10% FCS until they
were 50–70% confluent. Then cells were transfected with
expression plasmid encoding the protein CERT tagged with
GFP (CERT-GFP) or pcDNA3.1 empty vector using the
Lipofectamine 2000 reagent according to the manufacturer’s
directions.
[3H]Sphingosine metabolism
INS-1 cells, si-control (siCT) and si-CERT (siCERT) INS-1 cells
cultured in the presence of 5 mM or 30 mM glucose with or
without 0.4 mM palmitate for 12 h were pulsed with [3H]Sph
(0.3 mCi/ml), for 1 h maintaining the treatment conditions. All
experiments were performed at 37uC. Stock solutions of [3H]Sph
in absolute ethanol were prepared and added to fresh medium. In
all cases, the final concentration of ethanol never exceeded 0.1%
(v/v). At the end of pulse, cells were washed twice with phosphate-
buffered saline (PBS) at 4uC, harvested and submitted to lipid
extraction and partitioning as previously described [30]. The
methanolized organic phase and the aqueous phase were analyzed
by HPTLC using chloroform/methanol/water (55:20:3 by vol)
and chloroform/methanol/0.2% CaCl2 (55:45:10 by vol) as
solvent system respectively. Digital autoradiography of HPTLC
plates was performed with Beta-Imager 2000 (Biospace, France)
and the radioactivity associated with individual lipids was
measured using the software provided with the instrument. The
[3H]-labeled sphingolipids were recognized and identified as
previously described [30].
Liquid chromatography-tandem mass spectrometry
(LC-MS/MS) protocol for lipid extraction and
quantitation
Cellular lipids were extracted from INS-1 cells according to
Shaner et al. [31] with modifications. Briefly, freeze-dried INS-1
cells (2 million) were transferred to a 5 ml glass tube, spiked with
10 ml of internal standard (12.5 mM Ceramide/Sphingoid Internal
Mix I), and extracted with 2 ml of chloroform:methanol (1:2, v/v)
following brief sonication and constant agitation in a 50uC water
bath for 2 h. After cooling to room temperature, 200 ml of 1 M
KOH in methanol was added and incubated for 2 h at 37uC. After
cooling, 15 ml of glacial acetic acid were added to neutralize the
extract. Following centrifugation, the supernatant was transferred
to a new glass tube and the extraction was repeated with a further
2 ml of chloroform:methanol (1:2, v/v). The resulting superna-
tants were pooled and dried under a stream of N2. The lipids were
resuspended in 200 ml of mobile phase (mobile phase A: mobile
phase B, 1:1, v/v). After centrifugation, aliquots were used for LC-
MS analysis. Inorganic phosphate (Pi) content of extracts were
determined according to van Veldhoven and Mannaerts [32].
Peak areas were used for quantitation by comparison with the
peak areas of internal standards.
Chromatographic separation of lipids was performed with an
HPLC system consisting of a binary pump, auto sampler, column
oven (1200 RRLC, Agilent Technologies, http://www.chem.
agilent.com). The lipid molecules were separated using a
GeminiNX C18 analytical column (2.0 mm I.D. x 100 mm,
particle size 3 mm, Phenomenex, http://www.phenomenex.com).
Column oven and auto sampler temperatures were maintained at
45uC and 4uC, respectively. The mobile phase consists of solvent A
(15 mM ammonium formate (pH 4.0):MeOH:THF, 5:2:3) and
solvent B (15 mM ammonium formate (pH 4.0):MeOH:THF,
1:2:7). Elution was performed at a flow rate of 0.30 ml min-1 in a
binary gradient mode. The initial composition of mobile phase
was 65:35 (A:B), linearly changed to 70:30 (A:B) over 12 min, and
maintained this composition over 22 min, changed to initial
composition 65:35 (A:B) over 1 min, followed by 7 min of column
re-equilibration. Column eluant was directed to waste for the
initial 1 min.
The HPLC system was coupled online to an Agilent 6460 triple
quadrupole mass spectrometer (Agilent Technologies) equipped
with a Jet Stream ion source. Data were recorded in positive
ionization mode using electrospray ionization with nitrogen as the
nebulizing gas. The gas temperature and flow rate was 350uC and
10 l min21, and the sheath gas temperature and flow rate was
360uC and 12 l min21, respectively. The ESI needle voltage was
adjusted to 4000 V in positive mode and optimum fragmentor
voltages and collision energies were assigned by analysis of
reference compounds (SM (d18:0/12:0); Cer (d18:1/12:0); GlcCer
(d18:1/12:0); S1P (d18:1-P)) in selected ion and product ion
scanning mode to determine multiple-reaction monitoring (MRM)
conditions and mass spectrometric structural studies. MRM
detection was applied using nitrogen as the collision gas.
Analysis of the Intracellular Distribution of Fluorescent
Ceramides
INS-1 cells were plated and grown on a glass coverslip and
cultured as previously described. At the end of the treatments, the
cells were loaded with 2.5 mM BODIPY-C5-Cer or NBD-C6-Cer
(as 1:1 complex with fatty acid free BSA) in RPMI 1640 at 4uC for
30 min [23]. After loading, the cells were incubated 30 min at
37uC in RPMI 1640 containing 5 mM or 30 mM glucose 6
0.4 mM palmitate and fixed with 0.5% glutaraldehyde solution in
PBS for 10 min at 4uC. The specimens were immediately
observed and analyzed with a fluorescence microscope (Olympus
BX-50) equipped with a fast high resolution charge-coupled device
camera (Colorview 12) and an image analytical software (Analysis
from Soft Imaging System GmbH).
Analysis of Intracellular Localization of CERT-GFP by
Confocal microscopy
INS-1 cells plated at 26105 cell/cm2 were grown on a glass
coverslip and maintained 24 h in RPMI 1640 plus 10% FCS. The
cells were then transfected with the plasmid, CERT-GFP using
lipofectamine 2000 according to manufacturer’s instructions. 24 h
after transfection, cells were treated with 5 mM or 30 mM glucose
60.4 mM palmitate for 12 h and fixed with 0.5% glutaraldehyde
solution in PBS for 10 min at 4uC. The cells were then
permeabilized with 0.2% Triton X-100 for 30 min at room
temperature and stained with WGA-texas red. The specimens
were analyzed with a confocal microscope (Leica SP5).
Immunoblotting
Phosho-Akt and GRP78 immunoblotting were performed on
INS-1 cells lysed with lysis buffer (20 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% NP-40, 10 mM sodium fluoride, 1 mM
EDTA, 10 mM Na4P2O7, 1 mM Na3VO4, and the protease
inhibitor cocktail). Solubilized proteins were centrifuged at
14,0006g at 4uC for 10 min. Supernatants were subjected to
10% SDS polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes. Membranes were blocked for 1 h at
room temperature in Tris-buffered saline (10 mM Tris-HCl,
pH 7.4, 140 mM NaCl) containing 0.1% Tween-20 (TBS-T) and
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5% skim milk, and then incubated with primary antibodies against
phosho-Akt overnight at 4uC or against GRP78 1 h at room
temperature. Membranes were washed in TBS-T, and bound
antibodies visualized with horseradish peroxidase-coupled second-
ary antibodies (Santa Cruz Biotechnology) and chemiluminescent
substrate. The relative intensities of bands were quantified by
densitometry.
CERT immunoblotting were performed using wild type or si-
control and si-CERT transfected cells lysed with CERT buffer
(10 mM Tris-HCl pH 7.4, 0.25 mM sucrose, 0.5 mM phenyl-
methylsulfonyl fluoride, 10 mg/ml aprotinin, 5 mg/mL leupeptin,
5 mg/mL pepstatin), processed and analyzed as previously described
[23]. The membranes were stripped 30 minutes at 50uC in 2%
SDS, 100 mM DTT, 0.5 M Tris-HCl pH 6.8, washed in TBS-T
and incubated 1 hour in Tris-buffered saline (10 mM Tris-HCl,
pH 7.4, 140 mM NaCl) containing 0.1% Tween-20 (TBS-T) and
5% BSA and then incubated with the primary antibody against
phospho-serine 2 h at room temperature. Membranes were washed
in TBS-T and bound antibodies visualized with horseradish
peroxidase-coupled secondary antibodies (Santa Cruz Biotechnol-
ogy) and chemiluminescent substrate.
RNA isolation, reverse transcription and Real-Time PCR
INS-1 cells were plated and grown on a glass coverslip and
cultured as previously described. At the end of the treatments, total
RNA was isolated from INS-1 cells with the RNeasy mini kit and
treated with the RNase-free DNAse I. One microgram of RNA was
reverse transcribed using the iScript cDNA synthesis kit according
to manufacturer’s instructions. Real-Time PCR was performed
using the iQ5 Real-Time PCR detection system (Biorad Labora-
tories, Hercules, CA, USA). Specific SYBR green expression assays
(SYBR green super mix) for CERT and TBP (TATA-box-binding
protein) were carried out. Simultaneous amplification of the target
sequences was carried out as follows: 3 minutes at 95uC, 50 cycles
95uC 10 sec, 59uC 40 sec and 60uC 30 sec and 1 cycle of 60uC
3 minutes. Results were analyzed using the iQ5 optical system
software (Biorad Laboratories, Hercules, CA, USA). Relative gene
expression was determined using the 22DDCt method [33]. Data
were normalized to TBP expression (used as endogenous control)
and INS-1 G5 cells were used as calibrator.
Sphingomyelin synthase activity
INS-1 cells were plated and treated as described above. At the
end of the treatments, the cells were loaded with 2.5 mMNBD-C6-
Cer (as 1:1 complex with fatty acid free BSA) in RPMI 1640 at
4uC for 30 min. After loading, the cells were incubated 15 or
30 min at 37uC in RPMI 1640 with 5 mM glucose or 30 mM
glucose 60.4 mM palmitate. At the end of the incubation, cells
were immediately put at 4uC to stop the enzymatic reaction; lipids
were extracted with chloroform -methanol [34] and separated by
thin-layer chromatography (TLC) using chloroform/methanol/
0.1 M KCl (1:2:0.8 [vol/vol/vol]) as the developing solvent.
Fluorescence-labeled sphingomyelin was quantified with a lumi-
nescence spectrometer (LS50B PerkinElmer).
Other methods
Total protein amount was assayed with the Comassie Blue
based Pierce reagent, using BSA fraction V as standard.
Radioactivity was measured by liquid scintillation counting.
Statistical analysis
Statistical significance of differences was determined by one-way
ANOVA.
Results
Effect of palmitate and glucose on [3H]Sph metabolism in
INS-1 cells
Treatment for 12 h with 0.4 mM palmitate (G5P4), 30 mM
glucose (G30), or 0.4 mM palmitate plus 30 mM glucose (G30P4)
did not exert a toxic effect on INS-1 control cells treated with
5 mM glucose (G5) (Fig. 1a, left panel). A similar effect of
palmitate on cell viability was observed when assessing the protein
content of each dish, demonstrating that at 12 hours there is no
toxic effect on INS-1 cells (results not shown). After 24 hours,
palmitate or 30 mM glucose alone exerted no toxicity. We also
observed that 30 mM glucose increased INS-1 cell numbers, in
agreement with previously published report [12] (Fig. 1a). In
contrast, co-administration of 0.4 mM palmitate and 30 mM
glucose for 24 hours reduced INS-1 cell viability by 53% (Fig. 1a
right panel). Western blot analysis of GRP78, a ER stress marker,
showed that a 12 h co-treatment with 0.4 mM palmitate and
30 mM glucose induced about 60% increase in the amount of
GRP78 compared to 5 mM glucose with or without 0.4 mM
palmitate and 30 mM glucose in INS-1 cells (Fig. 1b), suggesting
that glucolipotoxic conditions induce ER stress. In the positive
control, we observed that 0.1 mM thapsigargin in the presence of
5 mM glucose doubled GRP78 levels in INS-1 cells (Fig. 1b). To
evaluate the effects of palmitate and high glucose concentrations
on Cer utilization for the biosynthesis of SM and GSLs in INS-1
cells, we studied Cer metabolism using [3H]-sphingosine as a
metabolic precursor as it is rapidly internalized in the cells and
efficiently N-acylated to Cer, which in turn is converted to SM,
glucosylceramide and complex GSLs. We performed short pulse
experiments to monitor the utilization of newly synthesized Cer for
the biosynthesis of SM and GlcCer [26]. In all cases, [3H]Sph was
mainly metabolized to N-acylated compounds, mostly represented
by Cer, SM and, in lower amounts, GSLs (Fig. 1c); the extent of
N-acylation being similar in all conditions. Treatment with
palmitate in the presence of 5 mM glucose significantly modified
the distribution of radioactivity between the different Sph
metabolites. Our results showed that palmitate induced [3H]Cer
accumulation was associated with a decrease of [3H]SM levels
(Fig. 1c). Treatment with 30 mM glucose by itself also reduced
[3H]Cer conversion to [3H]SM. Moreover, high glucose levels
strongly potentiated the reduced utilization of Cer for SM
biosynthesis induced by 0.4 mM palmitate, and also significantly
reduced GSL biosynthesis (Fig. 1c). The percent increase of
[3H]Cer was 23% and 14%, respectively in 5 mM glucose plus
palmitate, and in 30 mM glucose treated cells; in cells treated with
30 mM glucose plus palmitate [3H]Cer was 54% higher (Fig. 1c)
than in cells treated with 5 mM glucose. Conversely, the reduction
in [3H]SM was 32% and 23% in cells treated separately with
0.4 mM palmitate and 30 mM glucose, respectively, and 64% in
glucolipotoxic conditions, demonstrating that co-treatment with
30 mM glucose and palmitate has a greater effect than the sum of
the individual treatments (palmitate or 30 mM glucose) (Fig. 1c).
Taken together, these results showed that in pancreatic b-cells,
glucolipotoxicity can regulate the use of Cer for the biosynthesis of
complex sphingolipids in the Golgi apparatus.
Effect of palmitate and glucose on ceramide,
sphingomyelin and glucosylceramide molecular species
Next, we evaluated the effect of palmitate treatment on Cer, SM
and GlcCer mass levels, and the levels of their metabolic molecular
species by LC/MS/MS. Our data showed that palmitate, in the
presence of 5 mM glucose as well as 30 mM glucose alone, did not
significantly alter Cer, SM and GlcCer mass levels in INS-1 cells
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(Fig. 2); In contrast, palmitate with high glucose levels (30 mM)
promoted an increase in Cer mass levels with a concomitant
decrease in the mass levels of SM but not that of GlcCer. Our data
show that glucolipotoxic conditions led to an increase in saturated
ceramides, the greatest increase being observed in C18:0-Cer and
C22:0-Cer (Fig. 2). In addition, this condition mostly reduced the
levels of saturated SM and, more specifically, of C18:0-SM and
C24:0-SM (Fig. 2). In contrast, glucolipotoxicity did not appear to
alter significantly the levels of the different GlcCer molecular
species (Fig. 2). We also evaluated the effect of palmitate treatment
on S1P levels in INS-1 cells. Our data showed that at low levels of
glucose (5 mM), palmitate was unable to increase significantly S1P
levels in INS-1 cells. However, after a 12 h of treatment, palmitate
in the presence of 30 mM glucose promoted an increase in S1P
levels (Fig. 2) in agreement with the findings of Vere´t et al. [35].
Altogether, these data suggest that glucolipotoxicity induced an
increase in Cer levels and a reduction of SM levels in pancreatic b-
cells, but did not appear to significantly affect the amounts of
GlcCer.
Effect of palmitate and glucose on Sphingomyelin
Synthase activity
We then evaluated if the decrease in SM levels induced by
glucolipotoxicity is due to the inhibition of SM synthase (SMS)
activity using NBD-C6-Cer, a fluorescently labeled ceramide that
is an efficient substrate for SM synthases. Treatment with
palmitate in the presence of different glucose concentrations was
unable to alter the activity of SMS in INS-1 cells (data not shown),
suggesting that the activities of enzymes responsible for the
Figure 1. Palmitate and glucose regulate the use of Cer for the biosynthesis of complex sphingolipids in INS-1 cells. a) Cells were
treated for 12 h (left panel) or 24 h (right panel) with 0.4 mM palmitate (P4) or without palmitate in the presence of 5 mM or 30 mM glucose. Cell
viability was assessed by the MTT assay. Results are expressed as percentage of cell viability with respect to 5 mM glucose-treated cells (100%). Data
are the mean 6 S.D. of three independent experiments. *, p,0.05; ** p, ,0.01. b) INS-1 cells were treated with 5 mM or with 30 mM glucose
60.4 mM palmitate and harvested in lysis buffer for immunoblot analysis of GRP78 and GAPDH levels as described in experimental procedures. INS-1
cells were pretreated 30 min 60.1 mM thapsigargin (Tg). Equal amounts of protein from homogenates were analyzed by immunoblotting with an
anti-GRP78 antibody and an anti-GAPDH antibody. c) Cells were treated for 12 h 60.4 mM palmitate in the presence of 5 mM or 30 mM glucose and
then pulsed with 0.3 mCi/ml [C3-3H]sphingosine for 1 h. At the end of pulse, cells were harvested and submitted to lipid extraction and partitioning.
The methanolized organic phase and the aqueous phase were analyzed by HPTLC and digital autoradiography of HPTLC (see experimental
procedures). G5, 5 mM glucose; G5P4, 5 mM glucose+0.4 mM palmitate; G30, 30 mM glucose; G30P4, 30 mM glucose+0.4 mM palmitate. Data are
the mean 6 S.D. of at least three independent experiments. *p,0.05 for Ceramide and Sphingomyelin G5P4 or G30 compared with G5 and for GSLs
G30P4 compared with G30; **p ,0.01 for Cer and SM G30P4 compared with G30.
doi:10.1371/journal.pone.0110875.g001
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biosynthesis of SM were not affected by glucolipotoxic conditions
in INS-1 cells.
Effect of palmitate and glucose on intracellular
distribution of BODIPY-C5Cer and NBD-C6Cer
We then tested the possibility that glucolipotoxicity inhibited the
synthesis of complex sphingolipids, mainly represented by SM, by
affecting the transport of Cer synthesized in the ER to the Golgi
apparatus (where SM and GSL biosynthesis occurs). The transport
of natural Cer from the ER to the Golgi apparatus can be
qualitatively evaluated from the analysis of BODIPY-C5-Cer
redistribution in cells [34]. In 5 mM and 30 mM glucose-treated
INS-1 cells, most of the fluorescence accumulated in the
perinuclear region (Fig. 3a), which is representative of the Golgi
apparatus. In INS-1 cells treated with 0.4 mM palmitate together
with 5 mM glucose, fluorescence was also observed in the
perinuclear region but to a lesser extent compared to control cells
suggesting a partial defect in Cer traffic. (Fig. 3a). In contrast, co-
administration of 0.4 mM palmitate and 30 mM glucose strongly
reduced fluorescence accumulation in the Golgi apparatus region
(Fig. 3a), suggesting an impairment of ceramide flow from the ER
to the Golgi apparatus as a result of glucolipotoxicity in pancreatic
b-cells. In INS-1 cells, the presence of thapsigargin (Tg) which
induced ER stress in b-cells (Fig. 1b) [14] mimics the effect of high
glucose together with 0.4 mM palmitate by strongly reducing the
fluorescence accumulation in the Golgi apparatus region (Fig. 3a).
The effect of thapsigargin was not affected by the presence of
glucose or palmitate. In contrast, when cells were labeled with
NBD-C6Cer, which selectively localizes at the Golgi apparatus
[34], 5 mM and 30 mM glucose in the presence or absence of
0.4 mM palmitate with or without Tg did not modify the
accumulation of NBD fluorescence in the perinuclear Golgi
region (Fig. 3b). Altogether, these results suggest that glucolipo-
toxicity induce an impairment of ceramide flow from the ER to
the Golgi apparatus in pancreatic b-cells.
Figure 2. Chain-length specificity of ceramide, sphingomyelin and glucosylceramide in response to palmitate and high
concentrations of glucose in INS-1 cells. Cells were incubated with 0.4 mM palmitate in the presence of 5 mM (G5) or 30 mM (G30) glucose
for 12 h. Levels of N-acyl chain lengths of Cer, SM and GlcCer were determined by LC–MS/MS. Levels of S1P in INS-1 cells were also determined by LC-
MS/MS measurement. Results are expressed as pmol/nmol of phospholipids (PL) for Cer and SM and as fmol/nmol PL for GlcCer and S1P and are
means 6 S.D. for three independent experiments. *p,0.05 vs G5 except for S1P *p,0.05 vs G30.
doi:10.1371/journal.pone.0110875.g002
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Effect of palmitate and glucose on CERT levels and
activation
A recent report suggests that inhibition of CERT-mediated Cer
transport can exacerbate repression of pro-insulin gene expression
induced by long term treatment (48 h) with palmitate in INS-1
cells [36]. On this basis, we evaluated if a shorter treatment (12 h)
of INS-1 cells with palmitate and glucose can affect the levels and
the activation status of the protein CERT. Western blot analysis
showed that both 0.4 mM palmitate or 30 mM glucose alone did
not significantly alter the total amount of the CERT protein
(Fig. 4a and b) whereas co-treatment with 0.4 mM palmitate and
30 mM glucose induced a 65% reduction in the total amount of
CERT in INS-1 cells (Fig. 4a and b). Moreover, using an antibody
against phospho-serine according to Guo and co-workers [36], we
found that palmitate or 30 mM glucose alone did not modify
significantly the amount of phospho-CERT. Interestingly, co-
administration of 0.4 mM palmitate and 30 mM glucose doubled
the levels of phospho-CERT in INS-1 cells (Fig. 4a and c). In
order to assess how palmitate plus high glucose regulates CERT
levels, CERT expression was evaluated by quantitative PCR in
INS-1 cells. The results obtained (Fig. 4d) show that palmitate in
the presence of 30 mM glucose induced a 80% reduction in
steady-state levels of CERT transcripts, thus demonstrating that
glucolipotoxicity regulates CERT expression by inhibiting its
synthesis.
Effect of palmitate and glucose on CERT subcellular
localization
The phosphorylated form of CERT should have the PH
domain, the docking site for the Golgi apparatus, covered by the
START domain and should therefore not be able to colocalize
with the Golgi apparatus [37]. With this premise, we evaluated the
ability of CERT to localize at the Golgi apparatus in INS-1 cells as
a measure of CERT activity. To this purpose, we analysed the co-
localization of over-expressed CERT-GFP with the Golgi marker
WGA in INS-1 cells. The images obtained (Fig. 5a) showed that
Figure 3. Palmitate and glucose impairs ceramide flow from the ER to the Golgi apparatus in INS-1 cells. INS-1 cells grown on a glass
coverslip were pretreated 30 min 6 0.1 mM thapsigargin. At the end of the pretreatment, the cells were treated with or without palmitate in the
presence of 5 mM or 30 mM glucose for 12 h and then incubated with a) 2.5 mM BODIPY-C5Cer or b) 2.5 mM NBD-C6Cer as BSA complex 1:1 (m/m) in
DMEM for 30 min at 4uC; labeled cells were incubated at 37uC for 30 min and analyzed. All images were processed and printed identically.
doi:10.1371/journal.pone.0110875.g003
Glucolipotoxicity and Ceramide Traffic in Pancreatic b-Cells
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e110875
CERT and WGA co-localized in INS-1 cells treated with 5 mM
glucose in the presence or the absence of 0.4 mM palmitate, or
treated with 30 mM glucose. In contrast, co-treatment with
30 mM glucose and 0.4 mM palmitate significantly reduced co-
localization between CERT and WGA in INS-1 cells (Fig. 5a)
according to the Pearson’s colocalization coefficients (Fig. 5b).
Moreover when INS-1 cells were treated with 5 mM glucose in the
presence or absence of 0.4 mM palmitate, or treated with 30 mM
glucose alone, CERT and WGA co-localize in more than 90% of
the cells analysed (Fig. 5c). In contrast, in cells treated with 30 mM
glucose in the presence of 0.4 mM palmitate, co-localization of
CERT and WGA was detectable in only 8% of the cells (Fig. 5c).
Altogether, our results (Fig. 4 and 5) demonstrated that glucoli-
potoxicity can impair CERT-mediated Cer transport by reducing
both CERT levels and residual CERT activity through its
phosphorylation, a condition that reduces the capacity of CERT
to bind ceramide and prevent its localization to the Golgi
apparatus.
Effect of palmitate and glucose on [3H]Sph metabolism in
INS-1 cells silenced for CERT
On the basis of the results obtained, we next evaluated if CERT
silencing could mimic the defect in Cer utilization induced by
glucolipotoxicity. We examined the effects of palmitate with
30 mM glucose on [3H]Sph metabolism in control and CERT-
down-regulated INS-1 cells. We set up optimal conditions to
silence CERT and showed in the western blots that a $90%
reduction in CERT expression was achieved when cells were
transfected with a mixture of S87 and S522 (1:1 ratio) (Fig. 6a). As
expected, down regulation of CERT promoted a significant but
not complete reduction of Cer conversion to SM without
modifying the amount of synthesized GSLs (Fig. 6b). Palmitate
together with 30 mM glucose decreased Cer utilization for the
synthesis of SM and GSLs in control cells (siCT) but also in
siCERT ones (Fig. 6b). In particular, our results demonstrated that
glucolipotoxicity induced a 52% decrease in [3H]SM in siCT cells
and 65% in siCERT cells compared to cells treated with 30 mM
glucose in the absence of palmitate. These results suggest that
glucolipotoxicity, in addition to its effect on CERT, can also affect
vesicular-mediated Cer transport in pancreatic b-cells.
Effect of PI3K/Akt on [3H]Sph metabolism in INS-1 cells
treated with palmitate and glucose
We previously demonstrated [38] that the PI3K/Akt pathway
regulates the vesicular traffic of Cer in glioma cells, and we were
interested in the present study to examine if this was also the case
in INS-1 cells. We evaluated if a 12 h treatment with palmitate
and high glucose levels was able to regulate the PI3K/Akt
pathway in INS-1 cells. Western blot analysis with an antibody
specific for Akt phosphorylated at Ser473, demonstrated that
30 mM glucose did not modify pAkt levels but 0.4 mM palmitate
alone decreased pAkt levels and 0.4 mM palmitate together with
30 mM glucose induced a marked decrease of pAkt levels in INS-1
(Fig. 7a).
To investigate the effect of PI3K/Akt on Cer metabolism in
INS-1 cells, we utilized LY294002 and Wm as pharmacological
inhibitors of PI3K. We initially set up working concentrations to
specifically inhibit PI3K. To do this, we evaluated the capacity of
LY294002 and Wm to inhibit the PI3K/Akt pathway. Immuno-
blot analysis demonstrated that both 20 mM LY294002 and 10
nM Wm strongly reduced Akt activation (data not shown). INS-1
cells, treated with 5 mM or 30 mM glucose with or without
palmitate, were pulsed with [3H]Sph in the presence or absence of
LY294002 or Wm, and these last two molecules did not alter the
[3H]Sph uptake, determined as the radioactivity measured in the
total lipid extract (data not shown). In all cases, [3H]Sph was
mainly metabolized to N-acylated compounds (Fig. 7b–e) and the
extent of N-acylation (evaluated as the sum of tritiated Cer, SM
and GSLs) was always very similar in the control and treated cells.
However treatment with LY294002 or Wm strongly modified the
radioactivity distribution among the different Sph metabolites
both in the presence of 5 mM or 30 mM glucose (Fig. 7b and 7c).
In 5 mM glucose+LY294002 or 5 mM glucose+Wm treated INS-
1 cells, the radioactivity associated with [3H]Cer was 21% and
17% higher, respectively than that in 5 mM treated cells, with a
concomitant reduction of both [3H]SM and [3H]GSL levels (39%
and 29%, respectively in the presence of LY294002 and 32% and
27% respectively in the presence of Wm compared to 5 mM
treated cells) (Fig. 7b). Similarly, in cells treated with 30 mM
glucose, LY294002 and Wm promoted about 30% reductions in
synthesized SM and 20% decrease in GSL compared to 30 mM
glucose treated cells (Fig. 7c). Taken together these results suggest
that the PI3K/Akt pathway can regulate the metabolic utilization
of Cer through the modulation of the vesicular traffic of Cer,
favouring the maintenance of low Cer levels in INS-1 cells even
under conditions (high glucose) of reduced utilization of Cer for
the biosynthesis of complex sphingolipids. In cells treated with
5 mM glucose+palmitate, LY294002 or Wm slightly reduced the
amount of synthesized SM and GSL (Fig. 7d). In cells treated with
high glucose in the presence of palmitate (characterized by a
reduced utilization of Cer for the biosynthesis of complex
Figure 4. Palmitate and glucose regulate CERT expression and
activation in INS-1 cells. a) INS-1 cells were harvested in lysis buffer
as described in material and methods. Equal amounts of protein from
homogenates were analyzed by immunoblotting with an anti-CERT
antibody, an anti-phosphoserine and an anti-GAPDH antibody; b) the
amount of CERT expressed was determined by densitometric quanti-
tation and normalized for GAPDH **p,0.01 for G30+palmitate
compared with G30; c) the amount of pCERT expressed was determined
by densitometric quantitation and normalized for CERT **p,0.01 for
G30+palmitate compared with G30; d) Relative expression of CERT
assessed by Real-Time PCR. Results are expressed as fold-change
relative to G5 *p,0.05 G30+palmitate cells vs G30. Values are mean 6
SD of three independent experiments.
doi:10.1371/journal.pone.0110875.g004
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sphingolipids as shown in Fig. 1), LY294002 or Wm did not
further reduce the amount of synthesized SM and GSL (Fig. 7e).
Altogether, these data suggest that palmitate inhibits vesicular-
mediated Cer traffic through down-regulation of the PI3K/Akt
pathway, and this effect is potentiated in glucolipotoxic conditions,
thereby contributing to the accumulation of Cer in pancreatic b-
cells.
Discussion
The most relevant result obtained by this investigation is that in
pancreatic b-cells, glucolipotoxicity impairs Cer traffic from the
ER to the Golgi apparatus, thus promoting the accumulation of
Cer in the ER. As a model for mimicking glucolipotoxicity, we
incubated INS-1 cells with 0.4 mM palmitate in the presence of
high glucose concentrations (30 mM). This condition resulted in a
60% reduction in cell viability after a 24 h treatment. Studies
using [3H]Sph as a metabolic precursor showed that glucolipo-
toxicity strongly reduced the utilization of newly synthesized Cer
mainly for the biosynthesis of SM and, to a lesser extent, for
synthesis of GlcCer and complex GSLs. This occurred after a 12 h
treatment, when all INS-1 cells are still viable but show a
significant ER stress response (Fig. 1b). It is noteworthy that
palmitate-induced reduction of Cer utilization for complex
sphingolipid biosynthesis was strongly potentiated by high glucose
levels. As a consequence, the observation of increased Cer levels is
in agreement with previously published data [11,35]. We show for
the first time that this increase was associated with a significant
reduction of total SM but not of GlcCer levels in INS-1 cells.
Glucolipotoxic conditions does not significantly modify GlcCer
mass level but this does not exclude that the amount of complex
GSLs could be reduced. Moreover we cannot exclude that
glucosylceramide synthase is increased by palmitate as Boslem and
co-workers [20] have shown that palmitate increase GlcCer in
MIN6 b-cells. Interestingly, glucolipotoxicity lowered only satu-
rated SM species in b-cells, favouring the accumulation of
saturated Cer species such as C18:0-Cer, which are pro-apoptotic
in b-cells [12]. The decrease in SM biosynthesis suggests that
glucolipotoxicity could affect SM synthase activity and/or the
availability of its substrate by inhibiting Cer traffic from the ER to
the Golgi. However, the capacity of INS-1 b-cells to synthesize SM
from a diffusible substrate such as NBD-Cer is maintained,
indicating that SM synthase activity is preserved during glucoli-
potoxic conditions. The analysis of intracellular distribution of
Figure 5. Palmitate and glucose prevent colocalization of CERT and Golgi apparatus in INS-1 cells. INS-1 cells grown on a glass coverslip
were transfected with the plasmid CERT-GFP as described in experimental procedures. 24 h later, the cells were treated with or without palmitate in
the presence of 5 mM or 30 mM glucose for 12 h. Cells were then fixed and immunostained with WGA texas red-conjugated, a specific marker for the
Golgi apparatus. a) Representative confocal microscopy images are shown; all images were processed and printed identically. b) The co-localization
between CERT and WGA has been quantified through the Image J software and reported as Pearson colocalization coefficient. *p,0.05 G30+
palmitate cells vs G30. c) The percentage of cells with co-localization of CERT and WGA was determined. The data are means 6 the SD. **p,0.01 for
G30+palmitate compared with G30.
doi:10.1371/journal.pone.0110875.g005
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BODIPY-C5-Cer, which mimics the intracellular movements of
naturally occuring Cer [26,34,39], provided evidence that
glucolipotoxicity impairs the intracellular traffic of Cer from ER
to the Golgi apparatus in INS-1 b-cells, supporting the idea that,
under glucolipotoxic conditions, this mechanism can contribute to
the accumulation of Cer at the ER. Recent studies have shown
that specific accumulation of Cer at the ER due to palmitate can
induce ER stress and apoptosis of pancreatic b-cells [14,19,20,34].
This phenomenon could be alleviated by over-expression of
glucosylceramide synthase in b-cells, an enzyme which transforms
ceramide into glucosylceramide, thereby preventing excessive
accumulation of ceramide in the ER [20]. Importantly, our results
enforce the crucial role of Cer accumulation at the ER in induced
apoptosis and the loss of b-cell mass that contributes to the
development of type II diabetes. Moreover, our results confirmed
that glucolipotoxicity increased total S1P levels in INS-1 cells in
agreement with Ve´ret and co-workers [35] who showed that
palmitate treatment not only induce anti-apoptotic signals but also
pro-apoptotic signals such as the production of S1P. Evidence
from published literature [29] demonstrated that the decrease in
S1P levels is associated with Cer traffic impairment, leading us to
hypothesize that increased S1P levels are unlikely to be involved in
the initiation of defective ceramide transport. Additionally, the
increased in S1P levels are also unlikely to be sufficient to restore
normal ceramide trafficking in order to avoid ceramide accumu-
lation to counteract the effect of glucolipotoxicity.
Two main mechanisms are involved in ceramide transport from
the ER to the Golgi apparatus: a protein-mediated transport that
is mediated by CERT [23,24], and a CERT-independent
vesicular transport pathway [23,26]; our data demonstrate that
both of these pathways are strongly inhibited by glucolipotoxicity.
In relation to CERT, a 12 h treatment of b-cells with
glucolipotoxic conditions but not the treatment with high glucose
and palmitate separately, induced a significant decrease in the
total amount of the CERT protein and steady-state transcript
levels, suggesting a reduced rate of CERT protein synthesis in
glucolipotoxic conditions. In this respect, Granero et al. identified
a human-specific TNFa-responsive promoter for CERT [40] as a
possible mechanism of transcriptional CERT regulation. Howev-
er, we cannot exclude the possibility that, during glucolipotoxic
Figure 6. Palmitate and glucose affect vesicular-mediated Cer
transport. a) Cells were transfected with a mix of S87 and S522 siRNA
for CERT (siCERT) and the corresponding non-targeting corresponding
sequences as control (siCT) and harvested in lysis buffer 72 h after
transfection. 40 mg of protein from homogenate fractions and 2.4 ng of
recombinant CERT (CERT) were analyzed by immunoblotting with
polyclonal antibody anti-CERT and monoclonal anti-GAPDH. b) INS-1
cells down-regulated for CERT were treated for 12 h with or without
palmitate in the presence of 30 mM glucose. Then the cells were pulsed
with 0.3 mCi/ml [C3-3H]sphingosine for 1 h and processed and analyzed
as described in the legend of Fig. 1. Data are mean 6 S.D. of at least
three independent experiments. *p,0.05 for siCERT compared with
siCT and in GSL for siCT+palmitate vs siCT and siCERT+palmitate vs
siCERT; **p,0.01 for siCT+palmitate compared with siCT and for
siCERT+palmitate compared with siCERT.
doi:10.1371/journal.pone.0110875.g006
Figure 7. Palmitate and glucose inhibit vesicular-mediated Cer
traffic through downregulation of PI3K/Akt pathway. a) INS-1
cells were treated with 5 mM or with 30 mM glucose 60.4 mM
palmitate and harvested for immunoblot analysis of phospho-Akt and
GAPDH levels as described in experimental procedures. INS-1 cells were
pretreated 30 min with or without 20 mM LY294002. The cells were then
b) treated for 12 h with 5 mM glucose in the presence or absence of
LY294002 or of Wm; c) treated for 12 h with 30 mM glucose in the
presence or absence of LY294002 or Wm; d) treated for 12 h with 5 mM
glucose plus 0.4 mM palmitate in the presence or absence of LY294002
or Wm; e) treated for 12 h with 30 mM glucose plus 0.4 mM palmitate
in the presence or absence of LY294002 or Wm. Then cells were pulsed
1 h with [3H]Sph in the absence (opened and dotted bars) or presence of
20 mM LY294002 (striped bars) or 10 nM Wm (square bars). At the end of
pulse, cells were harvested and submitted to lipid extraction and
analyzed as described in the legend of Fig. 1. All values are the mean 6
S.D. of at least three individual experiments. *p,0.05 for Cer and GSLs
G5+LY294002 and G5+Wm compared with G5 and for GSLs G30+
LY294002 and G30+Wm compared with G30; **p,0.01 for SM G5+
LY294002 and G5+Wm compared with G5 and G30+LY294002 and
G30+Wm compared with G30.
doi:10.1371/journal.pone.0110875.g007
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stress, CERT could also be cleaved by caspase-3, an enzyme
highly activated by glucolipotoxicity in b-cells [12] as has been
proposed in Hela cells under pro-apoptotic stress [41]. Moreover
we also found that, under glucolipotoxic conditions, residual
CERT protein is highly phosphorylated and is no longer able to
localize at the Golgi apparatus in INS-1 cells. CERT specifically
targets the Golgi apparatus through its PH domain, which
selectively recognizes phosphatidyl-inositol-4-phosphate (PI-4P)
at the Golgi, and its hyperphosphorylation results in the repression
of PI4P binding activity of the PH domain [37]. Palmitate or
glucose alone did not modify either phosphorylation or CERT
localization. However, a recent paper [36] demonstrated that
short term exposure (3h) to palmitate increased phosphorylation of
CERT in INS-1 cells and this was associated with the inhibition of
insulin gene expression. This appears to suggest that acute and
chronic exposure to palmitate might differentially affect CERT
activity. Overall, glucolipotoxicity strongly decreases the amount
of active CERT and the amount of remaining CERT is mostly
inactive. Altogether, these data demonstrate that glucolipotoxicity
impairs the CERT-mediated Cer traffic from the ER to the Golgi
apparatus, thus supporting the idea that, under glucolipotoxic
conditions, this mechanism contributes to the accumulation of Cer
at the ER. Therefore, CERT is important not only in the
regulation of the insulin gene expression [36], but also in the
predisposition to b-cell death.
The vesicle-mediated pathway of Cer with the transport of a
thousand lipid molecules per transfer step could provide a feasible
mechanism to compensate for CERT defect in the bulk of SM
biosynthesis. We demonstrated that in INS-1 cells where
expression of CERT is silenced (a condition able to mimic the
effect of glucolipotoxicity on CERT), glucolipotoxic conditions are
still able to further decrease the metabolic utilization of Cer for the
synthesis of SM and GSLs, lending credence that vesicular traffic
of Cer is impaired. Additionally, we observed in INS-1 cells that
the PI3K/Akt pathway regulates Cer metabolism by controlling
the vesicular transport of Cer between the ER and the Golgi
apparatus, similar to glioma cells [38]. Glucolipotoxic conditions
promote a strong inhibition of the PI3K/Akt pathway, consistent
with previous studies showing that long-term exposure to
glucolipotoxic conditions and/or high palmitate decreases the
PI3K/Akt pathway in pancreatic b-cells [42–44]. Our experi-
ments also showed that palmitate alone partially decreased pAkt
levels and this was associated with the inhibition of Cer vesicular
traffic. The role of the PI3K/Akt pathway in mediating the effects
of palmitate and glucolipotoxicity on Cer vesicular flow is
confirmed by the evidence that the PI3K inhibitors, LY294002
and Wm, which are not effective in glucolipotoxic conditions, have
a slight effect on Cer flow in cells treated with palmitate in the
presence of 5 mM glucose, probably because palmitate alone only
partially inhibits pAkt. It is worth noting that the reduced Cer
utilization is higher than the simple sum of the effects induced by
the two single nutrients separately. The results of our study support
the idea that glucolipotoxicity inhibits the PI3K/Akt pathway in
pancreatic b-cells, which in turn inhibits the vesicular trafficking of
Figure 8. Schematic representation of the model showing the involvement of ceramide traffic in ER stress induced by
glucolipotoxicity. Glucolipotoxicity impairs CERT- and vesicular-mediated Cer traffic. Glucolipotoxicity decrease the amount of active CERT
significantly decreasing a) the total amount of the protein and b) the phosphorylation of CERT SR motif that is no longer able to localize at the Golgi
apparatus. Moreover glucolipotoxicity inhibits PI3K/Akt pathway that could in turn impairs vesicular trafficking of Cer from the ER to the Golgi
apparatus. Both transport systems contribute to the accumulation of Cer at the ER, thereby inducing ER stress. Furthermore ceramide synthase 4
(CerS4) [12] and serine palmitoyltransferase (SPT) [16,17], both residing in the endoplasmic reticulum (ER), have been shown to be involved in
regulating Cer levels in b-cells in response to lipotoxicity and/or glucolipotoxicity.
doi:10.1371/journal.pone.0110875.g008
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Cer. On the other hand, 30 mM glucose decreased the
biosynthesis of SM but does not modify pAkt levels and Cer
traffic suggesting that this effect on SM could be associated with
increased N-SMase activity, consistent with previous papers
[18,19] demonstrating that high glucose levels increased N-SMase
activity.
Altogether, our data demonstrate that the CERT- and
vesicular-mediated Cer trafficking pathways can separately con-
tribute to the control of sphingolipid metabolism and Cer levels in
INS-1 cells, thus participating in regulating the accumulation of
ER-associated Cer involved in the regulation of pancreatic b-cell
function and death during type II diabetes [14,20]. In support to
this new idea, Guo and co-workers recently showed that down-
regulation of CERT by specific siRNA potentiated palmitate-
induced inhibition of insulin gene expression in pancreatic b-cells
[36]. Moreover, these findings suggest that an impairment in ER
to Golgi Cer traffic can act synergistically, leading to enhanced de
novo Cer biosynthesis [12,16], resulting in accumulation of Cer in
the ER in response to glucolipotoxicity (Fig. 8).
Further understanding of the mechanisms that regulate the
accumulation of Cer at the ER will be important for developing
new strategies to prevent type II diabetes. Moreover, the capacity
of the PI3K/Akt pathway to regulate sphingolipid metabolism
may also be pathologically relevant in b-cells if we consider that
the PI3K/Akt pathway plays a crucial role in the control of b-cell
mass and function by modulating a dynamic balance of
proliferation, cell size and apoptosis [45].
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